search
Back to results

Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use

Primary Purpose

Vaginal Vault Prolapse, Pelvic Organ Prolapse, Uterine Prolapse

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Preoperative Pessary Use
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Vaginal Vault Prolapse focused on measuring Pessary, Prolapse, Cystocele

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Older than 18 years of age
  • With symptomatic pelvic organ prolapse
  • Electing for surgical repair of pelvic organ prolapse (transvaginal or transabdominal) at least 7 days after office consultation
  • Understand and have signed written informed consent for preoperative pessary placement.

Exclusion Criteria:

  • Previous use of a pessary for pelvic organ prolapse
  • Patients undergoing obliterative prolapse surgery (i.e. Colpocleisis),
  • Are scheduled for surgery for pelvic organ prolapse less than 7 days after office consultation or greater than 4 weeks after office consultation
  • Have an isolated rectocele
  • Have allergies to both latex and silicone
  • Have an active pelvic infection

Sites / Locations

  • Mayo Clinic

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Preoperative Pessary Use

Arm Description

All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse

Outcomes

Primary Outcome Measures

Patient Global Impression of Improvement (PGI-I) Score
Number of participants considered treatment success assessed using the 7-point Likert scale of the Patient Global Impression of Improvement (PGI-I) of 1= very much better and 7=very much worse. Patient's will be considered treatment success if they answer "much better" or "very much better" on the PGI-I scale.
Prolapse Symptom Severity
Mean value of score on self-reported Pelvic Organ Prolapse Distress Inentory-6 (POPDI-6) questionnaire. Minimum scale score = 0; maximum scale score = 100 and a higher score indicates worse outcome.
Bother of Bladder/Vaginal/Bowel Symptoms
Mean value of score on self-reported Floor Impact Questionnaire-7 (PFIQ-7). Minimum scale score = 0; maximum scale score = 100 and a higher score indicates worse outcome.
Overactive Bladder Symptom Score (OABSS)
Mean value of score on self-reported Overactive Bladder Symptom Score (OABSS) questionnaire. Minimum scale score = 0; maximum scale score = 15 and a higher score indicates worse outcome.

Secondary Outcome Measures

Full Information

First Posted
February 3, 2016
Last Updated
August 7, 2020
Sponsor
Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT02680145
Brief Title
Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use
Official Title
Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Completed
Study Start Date
March 11, 2016 (Actual)
Primary Completion Date
October 31, 2019 (Actual)
Study Completion Date
December 31, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a single center, prospective trial of pessary use prior to reconstructive pelvic floor surgery for pelvic organ prolapse. The goal of the study is to evaluate the change in pelvic floor symptoms with pessary use and subsequent reconstructive surgery. Additionally, we will assess the impact that preoperative pessary use has on patient self-reported preparedness for surgery.
Detailed Description
It is anticipated that this trial will define the clinical utility of routine preoperative pessary placement, and by shaping patient expectations and increasing preparedness for surgery, we anticipate improving satisfaction and quality of life. At the initial office visit baseline symptoms are evaluation with validated questionnaire. The patients' will undergo pessary fitting at least 7 days (but no more than 28 days) prior to scheduled surgical prolapse repair. Symptomatic change from baseline will be assessed with validated questionnaire preoperatively. The pessary will be removed at the time of surgery, and the patient will undergo surgical correction of their pelvic organ prolapse (including all restorative surgical procedures, abdominal and transvaginal). A concomitant anti-incontinence procedure will be performed at the discretion of the treating physician in consultation with the patient. The patients' symptomatic outcome from surgery will then be reassessed by validated questionnaire at 6 weeks and 3 months postoperatively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vaginal Vault Prolapse, Pelvic Organ Prolapse, Uterine Prolapse, Pelvic Floor Prolapse
Keywords
Pessary, Prolapse, Cystocele

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
58 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Preoperative Pessary Use
Arm Type
Experimental
Arm Description
All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse
Intervention Type
Device
Intervention Name(s)
Preoperative Pessary Use
Intervention Description
Pessary use for 1-4 weeks prior to surgical prolapse repair
Primary Outcome Measure Information:
Title
Patient Global Impression of Improvement (PGI-I) Score
Description
Number of participants considered treatment success assessed using the 7-point Likert scale of the Patient Global Impression of Improvement (PGI-I) of 1= very much better and 7=very much worse. Patient's will be considered treatment success if they answer "much better" or "very much better" on the PGI-I scale.
Time Frame
3 months postoperatively
Title
Prolapse Symptom Severity
Description
Mean value of score on self-reported Pelvic Organ Prolapse Distress Inentory-6 (POPDI-6) questionnaire. Minimum scale score = 0; maximum scale score = 100 and a higher score indicates worse outcome.
Time Frame
Baseline, 3 month post surgery
Title
Bother of Bladder/Vaginal/Bowel Symptoms
Description
Mean value of score on self-reported Floor Impact Questionnaire-7 (PFIQ-7). Minimum scale score = 0; maximum scale score = 100 and a higher score indicates worse outcome.
Time Frame
Baseline, 3 month post surgery
Title
Overactive Bladder Symptom Score (OABSS)
Description
Mean value of score on self-reported Overactive Bladder Symptom Score (OABSS) questionnaire. Minimum scale score = 0; maximum scale score = 15 and a higher score indicates worse outcome.
Time Frame
Baseline, 3 month post surgery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Older than 18 years of age With symptomatic pelvic organ prolapse Electing for surgical repair of pelvic organ prolapse (transvaginal or transabdominal) at least 7 days after office consultation Understand and have signed written informed consent for preoperative pessary placement. Exclusion Criteria: Previous use of a pessary for pelvic organ prolapse Patients undergoing obliterative prolapse surgery (i.e. Colpocleisis), Are scheduled for surgery for pelvic organ prolapse less than 7 days after office consultation or greater than 4 weeks after office consultation Have an isolated rectocele Have allergies to both latex and silicone Have an active pelvic infection
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John A Occhino, MD, MS
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Brian Linder, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Study Chair
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials

Learn more about this trial

Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use

We'll reach out to this number within 24 hrs